The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.
Main Areas of Focus:
- The focus of the program is to facilitate the advancement of promising drug candidates from bench to clinic.
- DAIDS is especially interested in the development of long acting formulations of antiretroviral drugs, as well as antiretroviral drugs targeting novel viral, and possibly host, proteins.